prostate cancer;t-therapy; psa; as

* Interestingly, when analyzing our data by individual patients, 16% exhibited an elevated PSA (≥1 ng/mL) throughout the one-year period. These patients had a median (IQR) baseline PSA of 3.5 (1.8–5.5) ng/mL, which was higher compared to the overall cohort. Notably, three of these patients...